São Paulo - Delayed Quote BRL

Hypera S.A. (HYPE3.SA)

Compare
18.03
-0.14
(-0.77%)
At close: December 27 at 6:07:56 PM GMT-3
Loading Chart for HYPE3.SA
DELL
  • Previous Close 18.17
  • Open 18.38
  • Bid 18.16 x --
  • Ask 18.20 x --
  • Day's Range 17.97 - 18.46
  • 52 Week Range 16.62 - 36.34
  • Volume 3,779,300
  • Avg. Volume 7,060,403
  • Market Cap (intraday) 11.407B
  • Beta (5Y Monthly) 0.44
  • PE Ratio (TTM) 7.33
  • EPS (TTM) 2.46
  • Earnings Date Mar 11, 2025 - Mar 17, 2025
  • Forward Dividend & Yield 1.40 (6.77%)
  • Ex-Dividend Date Sep 24, 2024
  • 1y Target Est 30.91

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.

www.hypera.com.br

10,301

Full Time Employees

December 31

Fiscal Year Ends

Recent News: HYPE3.SA

View More

Performance Overview: HYPE3.SA

Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

HYPE3.SA
48.21%
IBOVESPA
10.37%

1-Year Return

HYPE3.SA
48.08%
IBOVESPA
9.93%

3-Year Return

HYPE3.SA
29.90%
IBOVESPA
14.66%

5-Year Return

HYPE3.SA
40.77%
IBOVESPA
2.62%

Compare To: HYPE3.SA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HYPE3.SA

View More

Valuation Measures

As of 12/27/2024
  • Market Cap

    11.41B

  • Enterprise Value

    18.94B

  • Trailing P/E

    7.32

  • Forward P/E

    7.44

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.48

  • Price/Book (mrq)

    0.93

  • Enterprise Value/Revenue

    2.43

  • Enterprise Value/EBITDA

    7.00

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    21.14%

  • Return on Assets (ttm)

    6.27%

  • Return on Equity (ttm)

    14.65%

  • Revenue (ttm)

    8B

  • Net Income Avi to Common (ttm)

    1.69B

  • Diluted EPS (ttm)

    2.46

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.84B

  • Total Debt/Equity (mrq)

    86.49%

  • Levered Free Cash Flow (ttm)

    907.91M

Research Analysis: HYPE3.SA

View More

People Also Watch